Healthcare Triangle, Inc. (HCTI)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
CRITICAL DILUTION RISKDilution score: 83/100 (CRITICAL), 1.6 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 37.83% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Healthcare Triangle, Inc Signs MOU to Bring AI-Enabled Humanoid Nursing Robots to Hospitals in North America
- Healthcare Triangle Signs LOI for Proposed Roboticom Acquisition in $30 Million Deal
- Healthcare Triangle Signs Letter of Intent to Pursue the Proposed Acquisition of Roboticom's Cutting-Edge Industrial Precision Robotics Automation Business
- Healthcare Triangle (Nasdaq: HCTI) Joins Kanzun-ARCB Growth Fund to Build Malaysia-to-US Corridor for AI and Healthcare Companies
- HCTI Spins off Teyame to Benefit Shareholders
- Healthcare Triangle, Inc. to Distribute Minority Interest of Teyame AI Holdings Inc. Common Shares in Stock Dividend Distribution to HCTI Shareholders, In Connection with its Planned Direct Listing.
- Healthcare Triangle Reports 322% Increase in Gross Profit and 158% Increase in Revenue for Q2 2026
- Healthcare Triangle Signs Non-Binding LOI to Acquire 51% of CosmoInnovations; Enters High-Growth Proprietary MedTech and Consumer-Health Markets
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Healthcare Triangle, Inc..
Full HCTI Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.